SEC Filing Analysis: GE HealthCare Technologies Inc. (GEHC)

Executive Summary

• Trading Significance: Low
• Key Takeaway: CFO James Saccaro received routine annual equity compensation in the form of RSUs and Stock Options.
• Market Impact: Neutral; standard executive retention package with no direct market signaling.

Company Information

Field	Value
Company	GE HealthCare Technologies Inc.
Ticker Symbol	GEHC
CIK	0001932393
Industry	Medical Devices/Healthcare

Insider Information

Field	Value
Name	James Saccaro
CIK	0001593636
Title/Position	Chief Financial Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-03-02
Transaction Code	A (Grant/Award)
Security Type	Common Stock (RSUs) & Options
Shares Involved	12,475 (RSUs)
Price Per Share	$0.00
Total Value	$0 (Compensation Grant)
Shares Owned After	84,161
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Market Cap	$38.41 Billion
Shares Outstanding	455,750,000
Shares Transacted	12,475
% of Shares Outstanding	~0.0027%
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: With a market cap of $38.41B, this compensation grant is financially immaterial to the company's balance sheet.
• Ownership Concentration: The insider holds approximately 0.018% of the company following this transaction.
• Dilution Impact: The issuance of ~12.5k RSUs and ~32.8k options represents negligible dilution (<0.01%) to existing shareholders.
• Transaction Significance: This is a Code 'A' transaction (Grant), indicating compensation rather than an open market purchase or sale. It reflects the board's continued alignment of executive incentives with shareholder value.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Routine equity grants are expected operational events for large-cap companies and do not signal immediate price movement.

Volume & Sentiment

• Expected Volume Impact: None.
• Sentiment Indicator: Neutral.

Additional Context

Transaction Notes

• Vesting Schedule: Both the RSUs and Options vest over a three-year period (33% in 2027, 33% in 2028, 34% in 2029), ensuring long-term retention.
• Derivative Transaction: In addition to the RSUs, the insider was granted 32,797 stock options with an exercise price of $80.16, expiring in 2036.